TNFRSF8 and Hodgkins lymphoma: The unconjugated cAC10 antibody SGN-30 (Wahl et al, 2002) and SGN-35 are both under evaluation in clinical trials for the treatment of CD30-positive haematological malignancies, including ALCL and HL (Schnell & Borchmann, 2006).